To improve the outcome of orthotopic liver transplantation (OLT), knowledge of early molecular events occurring upon ischemia/reperfusion is essential. Powerful approaches for profiling metabolic changes in tissues and biofluids are now available. Our objective was to investigate the applicability of two technologies to a small but well-defined cohort of patients undergoing OLT: consecutive liver biopsies by Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) and microdialysates of extracellular fluid by coulometric electrochemical array detection (CEAD). FT-ICR MS detected reproducibly more than 4,000 peaks, revealing hundreds of significant metabolic differences between pre- and postreperfusion grafts. These included increased urea production, bile acid synthesis and clearance of preservation solution upon reperfusion, indicating a rapid resumption of biochemical function within the graft. FT-ICR MS also identified successfully the only graft obtained by donation-after-cardiac-death as a “metabolic outlier.” CEAD time–profile analysis showed that there was considerable change in redox-active metabolites (up to 18 h postreperfusion), followed by their stabilization. Collectively these results verify the applicability of FT-ICR MS and CEAD for characterizing multiple metabolic pathways during OLT. The success of this proof-of-principle application of these technologies to a clinical setting, considering the potential metabolic heterogeneity across only eight donor livers, is encouraging.
AzewrS.A., McCaughanG.W., StaceyN.H.1994. Daily determination of individual serum bile acids allows early detection of hepatic allograft dysfunction. Hepatology, 20:1458–1464.
3.
BaumgarnerU., ScholmerichJ., KremerB., StreckfussG., Henne-BrunsD., MergardB.L.et al.1995. Early detection of graft dysfunction after orthotopic liver transplantation in man by serum and biliary bile acid analysis. Hepatogastroenterology, 42:950–960.
4.
BerrevoetF., SchaferT., VollmarB., MengerM.D. 2003. Ischemic preconditioning: enough evidence to support clinical application in liver surgery and transplantation?Acta Chir Belg, 103:485–489.
5.
BijlsamaS., BobeldijkI., VerheijE.R., RamakerR., KochharS., MacDonaldI.A.et al.2006. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem, 78:567–574.
6.
BilzerM., GerbesA.L.2000. Preservation injury of the liver: mechanisms and novel therapeutic strategies. J Hepatol, 32:508–515.
7.
CariniR., AlbanoE.2003. Recent insights on the mechanism of liver preconditioning. Gastroenterology, 125:1480–1491.
8.
ClavienP.A., HarveyP.R., StrasbergS.M.1992. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation, 53:957–978.
9.
ContiA., ScalaS., D'AgostionP., AlimentiE., MorelliD., AndriaB.et al.2007. Wide gene expression profiling of ischemia–reperfusion injury in human liver transplantation. Liver Transplant, 13:99–113.
10.
DefamieV., CursioR., BirgandK.L., MoreilhonC., Saint-PaulM.C., LaurensM.et al.2008. Gene expression profiling of human liver transplants identifies an early transcriptional signature associated with initial poor graft function. Am J Transplant, 8:1221–1236.
11.
DuarteI.F., StanleyE.G., HolmesE., LindonJ.C., GilA.M., HuiruT.et al.2005. Metabolic assessment of human liver transplants from biopsy samples at the donor and recipient stages using high-resolution magic angle spinning H NMR spectroscopy. Anal Chem, 77:5570–5578.
12.
EugeneM., Le MoyecL., De CertainesJ., DesruennesM., Le RumeurE., FraysseJ.B.et al.1991. Lipoproteins in heart transplantation: proton magnetic resonance spectroscopy of plasma. Magn Reson Med, 18:93–101.
13.
Fernandez-MerinoJ., Garza-NunoJ., Lopez-HervasP., Lopez-BuenadichaA., Quijano-CollazoY., Vicent-LopezE.2003. Influence of ischemia and surgery times on development on primary dysfunction liver transplant in patients. Transplant Proc, 35:1439–1441.
GriffithsW.J.2008. Metabolomics, metabonomics and metabolite profiling. (The Royal Society of Chemistry, Cambridge).
16.
HanJ., DanellR.M., PatelJ.R., GumerovD.R., ScarlettC.O., SpeirJ.P.et al.2008. Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry. Metabolomics, 4:128–140.
17.
HansenT.N., DawsonP.E., BrockbankK.G.1994. Effects of hypothermia upon endothelial cells: mechanism and clinical importance. Cryobiology, 31:101–106.
18.
KanehisaM., ArakiM., GotoS., HattoriM., HirakawaM., ItohM.et al.2008. KEGG for linking genomes to life and the environment. Nucleic Acids Res, 36:D480–D484.
19.
KanehisaM., GotoS.2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res, 28:27–30.
20.
KanehisaM., GotoS., HattoriM., Aoki-KinoshitaK.F., ItohM., KawashimaS.et al.2006. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res, 34:D354–D357.
21.
KangK.J.2002. Mechanism of hepatic ischemia/reperfusion injury and protection against reperfusion injury. Transplant Proc, 34:2659–2661.
22.
KebarleP.2000. A brief overview of the present status of the mechanisms involved in electrospray mass spectrometry. J Mass Spectrom, 35:804–817.
23.
LemasteresJ.J., ThurmanR.G.1997. Reperfusion injury after liver preservation for transplantation. Annu Rev Pharacol Toxicol, 37:327–338.
24.
MaoYY., BaiJQ., ChenJH., ShouZF., HeQ., WuJY.et al.2008. A pilot study of GC/MS-based serum metabolic profiling of acute rejection in renal transplantation. Transplant Immunol, 19:74–80.
25.
MartensH., MartensM.2001. Analysis of One Data Table X: Principal Component Analysis. John Wiley & Sons Ltd: London.
26.
Mouly-BandiniA., Vion-DuryJ., VioutP, SciakyM., MesanaT., CozzoneP.J.2000. Detection of acute cardiac rejection by high resolution proton magnetic spectroscopy of plasma. Magma, 11:27–32.
27.
NicholsonJ.K., LindonJ.C.2008. Systems biology—metabonomics. Nature, 455:1054–1056.
28.
ParsonH.M., LudwigC., GuntherU.L., ViantM.R.2007. Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilizing generalized logarithm transformation. BMC Bioinformatics, 8:234–250.
29.
PayneT.G., SouthamA.D., ArvanitisT.N., ViantM.R.2009. A signal filtering method for improved quantification and noise discrimination in fourier transform ion cyclotron resonance mass spectrometry-based metabolomics data. J Am Soc Mass Spectrom, 20:1087–1095.
30.
ReddyS., ZilvettiM., BrockmannJ., McLarenA., FriendP.2004. Liver transplantation from non-heart-beating donors: current status and future prospects. Liver Transpl, 10:1223–1232.
31.
SarwalM.2009. Deconvoluting the “omics” for organ transplantation. Curr Opin Organ Transplant, 14:544–551.
32.
SerkovaN.J., ZhangY., CoatneyJ.L., HunterL., WachsM.E., NiemannC.U.et al.2007. Early detection of graft failure using the blood metabolic profile of a liver recipient. Transplantation, 83:517–521.
33.
SilvaM.A., RichardsD.A., BramhallS.R., AdamsD.H., MirzaD.F., MurphyN.2005. A study of the metabolites of ischemia–reperfusion injury and selected amino acids in the liver using microdialysis during transplantation. Transplantation, 79:828–835.
34.
SinghH.K., YachhaS.K., SaxenaR., GuptaA., Nagana GowdaG.A., BhandariM.et al.2003. A new dimension of 1H-NMR spectroscopy in assessment of liver graft dysfunction. NMR Biomed, 16:185–188.
35.
SouthamA.D., PayneT.G., CooperH., ArvanitisT.N., ViantM.R.2007. Dynamic range and mass accuracy of widescan direct infusion nanoelectrospray Fourier transform ion cyclotron resonance mass spectrometry-based metabolomics increased by the spectral stitching method. Anal Chem, 79:4595–4602.
36.
StahlJ.E., KrekeJ.E., MalekF.A.A., SchaeferA.J., VacantiJ.2008. Consequences of cold-ischemia time on primary nonfunction and patient and graft survival in liver transplantation: a meta-analysis. PLoS ONE, 3:1–11.
37.
StenlundH., MadsenR., ViviA., CalderisiM., LundstedtT., TassiniM.et al.2009. Monitoring kidney-transplant patients using metabolomics as dynamic modelling. Chemometr Intelligent Lab Syst, 98:45–50.
38.
TaylorN.S., WeberR.J.M., SouthamA.D., PayneT.G., HrydziuszkoO., ArvanitisT.N.et al.2009. A new approach to toxicity testing in Daphnia magna: an application of high throughput FT-ICR mass spectrometry metabolomics. Metabolomics, 5:44–58.
39.
TekinK., ImberC.J., AtliM., GunsonB.K., BramhallS.R., MayerD.et al.2004. A simple scoring system to evaluate the effects of cold ischemia on marginal liver donors. Transplantation, 77:411–416.
40.
TongH., BellD., TabeiK., SiegelM.M.1999. Automated data messaging, interpretation and e-mailing modules for high throughput open access mass spectrometry. J Am Soc Mass Spectrom, 10:1174–1187.
41.
VascottoC., CesarattoL., D'AmbrosioC., ScaloniA., AvelliniC., ParonI.2006. Proteomics analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation. Proteomics, 6:3455–3465
42.
ViantM.R., BeardenD.W., BundyJ.G., BurtonI.W., ColletteT.W., EkmanD.R.et al.2008. International NMR-based environmental metabolomics intercomparison exercise. Environ Sci Technol, 43:219–225.
43.
WishartD.S.2005. Metabolomics: the principles and potential applications to transplantation. Am J Transplant, 5:2814–2820.
44.
WuH., SouthamA.D., HinesA., ViantM.R.2008. High throughput tissue extraction protocol for NMR- and MS-based metabolomics. Anal Biochem, 372:204–212.
